Patents by Inventor Andrew Douglas Baxter

Andrew Douglas Baxter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hydroxamic and carboxylic acid derivatives
    Publication number: 20020022635
    Abstract: A phacologically actve compound of forula (1) 1
    Type: Application
    Filed: May 15, 2001
    Publication date: February 21, 2002
    Inventors: Duncan Robert Hannah, Hazel Joan Dyke, Robert John Watson, John Fraser Keily, Andrew Douglas Baxter
  • Hydroxamic and carboxylic acid derivatives
    Publication number: 20020013333
    Abstract: A pharmacologically active compound of formula (I) 1
    Type: Application
    Filed: May 15, 2001
    Publication date: January 31, 2002
    Inventors: Duncan Batty, Verity Margaret Sabin, Robert John Watson, Hazel Joan Dyke, Andrew Sharpe, Richard John Davenport, David Alan Owen, Andrew Douglas Baxter
  • Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
    Patent number: 6310088
    Abstract: Compounds of formula (I) are useful therapeutic agents, by virtue of having MMP and TNF inhibitory activity.
    Type: Grant
    Filed: May 4, 2000
    Date of Patent: October 30, 2001
    Assignee: Darwin Discovery, Ltd.
    Inventors: Andrew Douglas Baxter, David Alan Owen, John Gary Montana, Elizabeth Jane Reed Nicholson
  • Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
    Patent number: 6187924
    Abstract: Compounds of formula (I) are useful as therapeutic agents, by virtue of having MMP and TNF inhibitory activity.
    Type: Grant
    Filed: November 12, 1998
    Date of Patent: February 13, 2001
    Assignee: Darwin Discovery, Ltd.
    Inventors: Andrew Douglas Baxter, David Alan Owen, John Gary Montana, Robert John Watson
  • Peptidyl compounds
    Patent number: 6180611
    Abstract: Compounds of general formula (I): have utility as inhibitors of matrix metalloproteinases and TNF.
    Type: Grant
    Filed: May 20, 1999
    Date of Patent: January 30, 2001
    Assignee: Darwin Discovery, Ltd.
    Inventors: John Montana, Andrew Douglas Baxter, David Alan Owen, Robert John Watson, Neil Phillipson
  • Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
    Patent number: 6118001
    Abstract: Disclosed are hydroxamic and carboxylic acid derivatives which are useful inhibitors of matrix metalloproteinase and/or TNF.alpha.-mediated diseases, including degenerative diseases and certain cancers.
    Type: Grant
    Filed: August 7, 1997
    Date of Patent: September 12, 2000
    Assignee: Darwin Discovery, Ltd.
    Inventors: David Alan Owen, John Gary Montana, John Fraser Keily, Robert John Watson, Andrew Douglas Baxter
  • Peptidyl compounds having MMP and TNF inhibitory activity
    Patent number: 6114372
    Abstract: Compounds of formula (I) having MMP and TNF inhibitory activity.
    Type: Grant
    Filed: October 2, 1998
    Date of Patent: September 5, 2000
    Assignee: Darwin Discovery Limited
    Inventors: Andrew Douglas Baxter, David Alan Owen, John Gary Montana, Robert John Watson, John Fraser Keily
  • Peptidyl compounds and their therapeutic use
    Patent number: 6110896
    Abstract: Tripeptidyl derivatives having a SH or acylS group and which are amides, have therapeutic utility via MMP or TNF inhibition.
    Type: Grant
    Filed: May 10, 1996
    Date of Patent: August 29, 2000
    Assignee: Darwin Discovery, Ltd.
    Inventors: Andrew Douglas Baxter, John Montana, David Alan Owen
  • Hydroxamic and carboxylic acid derivatives
    Patent number: 6100266
    Abstract: For the treatment of cancer, inflammation, and other conditions associated with matrix metalloproteinases or that are mediated by TNF.alpha. or enzymes involved in the shedding of L-selectin, CD23, the TNF receptors, IL-1 receptors, or IL-6 receptors, disclosed are compounds of the general formulaB--X--(CH.sub.2).sub.m --(CR.sup.1 R.sup.2).sub.n --W--COY.
    Type: Grant
    Filed: January 29, 1999
    Date of Patent: August 8, 2000
    Assignee: Darwin Discovery Limited
    Inventors: John Gary Montana, Andrew Douglas Baxter, David Alan Owen
  • Peptidyl compounds having MMP and TNF inhibitory activity
    Patent number: 6090840
    Abstract: The subject invention concerns mercaptoalkylacyl compounds of formula (I): ##STR1## The compounds of the subject invention can be used to inhibit matrix metalloproteinases and/or TNF.alpha.- and L-selectin sheddase-mediated diseases including degenerative diseases and cancers. The subject invention also concerns methods of using the compounds of the invention to treat or prevent conditions associated with matrix metalloproteinases or that are mediated by TNF.alpha. or L-selectin sheddase.
    Type: Grant
    Filed: October 5, 1998
    Date of Patent: July 18, 2000
    Assignee: Darwin Discovery Limited
    Inventors: Andrew Douglas Baxter, David Alan Owen, John Gary Montana, Robert John Watson, John Fraser Keily
  • Heterocyclic compounds having MMP and TNF inhibitory activity
    Patent number: 6063786
    Abstract: Compounds of formula (I) ##STR1## are useful as therapeutic agents, by virtue of having MMP and TNF inhibitory activity.
    Type: Grant
    Filed: November 12, 1998
    Date of Patent: May 16, 2000
    Assignee: Darwin Discovery, Ltd.
    Inventors: Andrew Douglas Baxter, David Alan Owen, John Gary Montana
  • Peptidyl compounds
    Patent number: 6048841
    Abstract: Peptidyl compounds having an imidazole substituent have therapeutic utility via their inhibitory effect on metalloproteinases and tumour necrosis factor.
    Type: Grant
    Filed: November 22, 1996
    Date of Patent: April 11, 2000
    Assignee: Darwin Discovery, Ltd.
    Inventors: Andrew Douglas Baxter, John Gary Montana
  • Peptidyl compounds and their therapeutic use
    Patent number: 5994293
    Abstract: Dipeptidyl derivatives having a SH of acylS group and which are amides, thioamides or S(O).sub.0-2 -amides, have therapeutic utility via MMP or TNF inhibition.
    Type: Grant
    Filed: May 10, 1996
    Date of Patent: November 30, 1999
    Assignee: Darwin Discovery Ltd.
    Inventors: Andrew Douglas Baxter, John Montana, David Alan Owen
  • Peptidyl compounds
    Patent number: 5994312
    Abstract: Compounds of general formula (I): ##STR1## have utility as inhibitors of matrix metalloproteinases and TNF.
    Type: Grant
    Filed: July 30, 1998
    Date of Patent: November 30, 1999
    Assignee: Darwin Discovery, Ltd.
    Inventors: John Montana, Andrew Douglas Baxter, David Alan Owen, Robert John Watson, Neil Phillipson
  • Peptidyl compounds and their therapeutic use
    Patent number: 5981491
    Abstract: Peptidyl compounds have therapeutic utility via MMP/TNF inhibition.
    Type: Grant
    Filed: April 7, 1997
    Date of Patent: November 9, 1999
    Assignee: Darwin Discovery Limited
    Inventors: Andrew Douglas Baxter, John Montana, David Alan Owen
  • Peptidyl compounds
    Patent number: 5981490
    Abstract: Dipeptide compounds have therapeutic utility, inter alia, as metalloproteinase and TNF inhibitors.
    Type: Grant
    Filed: October 4, 1996
    Date of Patent: November 9, 1999
    Assignee: Darwin Discovery, Ltd.
    Inventors: Andrew Douglas Baxter, John Gary Montana, David Alan Owen
  • Peptidyl compounds having MMP and TNF inhibitory activity
    Patent number: 5955435
    Abstract: Peptidyl compounds have therapeutic utility via MMP and TNF inhibitory activity.
    Type: Grant
    Filed: August 8, 1997
    Date of Patent: September 21, 1999
    Assignee: Darwin Discovery Limited
    Inventors: Andrew Douglas Baxter, John Gary Montana
  • Quinolones and their therapeutic use
    Patent number: 5891878
    Abstract: 1-Alkyl-substituted-quinolone-3-carboxamides have therapeutic utility via inhibition of Phosphodiesterase IV esterase and/or Tumour Necrosis Factor activity. The compounds of the invention have the general formula (I): ##STR1## The compounds of the invention encompassed by formula (I) include enantiomers, diastereoisomers and mixtures, including racemic mixtures.
    Type: Grant
    Filed: August 2, 1996
    Date of Patent: April 6, 1999
    Assignee: Chiroscience Limited
    Inventors: Steven Colin Beasley, John Gary Montana, Hazel John Dyke, Alan Findlay Haughan, Karen Ann Runcie, David Thomas Manallack, George Martin Buckley, Robert James Maxey, Hannah Jayne Kendall, Andrew Douglas Baxter
  • Mercapto alkyl peptidyl compounds having MMP and TNF inhibitory activity
    Patent number: 5872146
    Abstract: Described herein are compounds of formula (I): ##STR1## which have MMP and TNF inhibitory activity.
    Type: Grant
    Filed: April 4, 1997
    Date of Patent: February 16, 1999
    Assignee: Chiroscience Limited
    Inventors: Andrew Douglas Baxter, John Gary Montana, David Alan Owen
  • Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases
    Patent number: 5853623
    Abstract: The present invention concerns novel mercaptoalkylpeptidyl compounds of formula (I) which are useful inhibitors of matrix metalloproteinase and/or TNF-mediated diseases including degenerative diseases and certain cancers. The invention also concerns methods of treating patients suffering from disorders or diseases which can be attributed to or are associated with matrix metalloproteinase or TNF activity.
    Type: Grant
    Filed: May 10, 1996
    Date of Patent: December 29, 1998
    Assignee: Chiroscience Limited
    Inventors: John Montana, David Alan Owen, Jonathan Dickens, Andrew Douglas Baxter